Loading
Loading
Research Overview
Single-chain derivative of the relaxin-2 B-chain; selective RXFP1 agonist that preserves anti-fibrotic signalling in cardiac, renal, and pulmonary tissues via collagen remodelling pathways while reducing the vasodilatory effects of full-length relaxin.
B7-33 was designed as a selective RXFP1 agonist that preserves the anti-fibrotic signalling of the relaxin-2 hormone while reducing its vasodilatory and blood-pressure-lowering properties. Full relaxin has demonstrated anti-fibrotic activity in preclinical models but causes significant haemodynamic effects that limit its therapeutic utility — B7-33's selective design aims to separate anti-fibrotic efficacy from cardiovascular side effects.
Preclinical research using B7-33 has examined fibrotic disease markers in cardiac, pulmonary, and renal tissue models. The compound is administered subcutaneously in animal studies and has been shown to activate RXFP1-mediated signalling cascades associated with extracellular matrix remodelling and collagen turnover.
B7-33 remains in very early preclinical stages with no published human safety or efficacy data. It represents a research tool for understanding RXFP1 biology and the role of the relaxin pathway in fibrotic disease rather than an established protocol compound. Community adoption is extremely limited.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, b7-33 has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
B7-33 research is most relevant to protocols examining:
Anti-fibrosis research in cardiac, renal, and pulmonary tissues
RXFP1 relaxin receptor biology studies
Collagen remodelling and fibrotic disease model investigations
Researchers studying RXFP1 agonists with reduced vasodilatory side effects
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Downstream biological effects become detectable. Key biomarkers worth monitoring from this point.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~2 hours). Review data, confirm baseline recovery before any repeat protocol.
Single-chain derivative of the relaxin-2 B-chain; selective RXFP1 agonist that preserves anti-fibrotic signalling in cardiac, renal, and pulmonary tissues via collagen remodelling pathways while reducing the vasodilatory effects of full-length relaxin.
| Parameter | Value |
|---|---|
| Dose range | No human protocol established |
| Schedule | Animal models only |
| Route | Subcutaneous |
| Half-life | ~2 hours |
preclinical only
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.